Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ATP4A | P20648 | 1/20 | 0.30 |
| ▸ | ATP4B | P51164 | 1/20 | 0.30 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566631 | 1.00 | KDM4E (0.35) | KDM4ECYP3A4CYP2C9ATP4AATP4B | |
| SCHEMBL5567312 | 0.85 | ATP4A (0.43) | KDM4ECYP3A4CYP2C9ATP4AATP4B | |
| SCHEMBL4888725 | 0.85 | ATP4A (0.43) | KDM4ECYP3A4CYP2C9ATP4AATP4B | |
| SCHEMBL5566826 | 0.85 | ATP4A (0.43) | KDM4ECYP3A4CYP2C9ATP4AATP4B | |
| SCHEMBL5566402 | 0.83 | CYP3A4 (0.33) | CYP3A4CYP2C9ATP4AATP4B | |
| SCHEMBL5569799 | 0.83 | CYP3A4 (0.33) | CYP3A4CYP2C9ATP4AATP4B | |
| SCHEMBL5571355 | 0.83 | CYP3A4 (0.33) | CYP3A4CYP2C9ATP4AATP4B | |
| SCHEMBL5569811 | 0.82 | RIPK1 (0.41) | CYP3A4CYP2C9ATP4AATP4B | |
| SCHEMBL5570783 | 0.82 | RIPK1 (0.41) | CYP3A4CYP2C9ATP4AATP4B | |
| SCHEMBL5570722 | 0.81 | ATP4A (0.35) | KDM4ECYP3A4CYP2C9ATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | GIPR, SLC10A2, GRPR | KDM4E 4244/4885CYP3A4 72/4885CYP2C9 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.